Parameters involved in the recognition of fresh human leukemic blasts by tumor-specific cytolytic T cell clones: A model study

Leukemia Research

Volumn 24, Issue 10, 2000, Pages 823-830

  Chambost, Hervé ^a,b   Collette, Yves ^a   Dutartre, Hélène ^a   Thuret, Isabelle ^b   Olive, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

CTL; HLA class I; Leukemia; MAGE genes; Tumor antigen

Indexed keywords

CD8 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; RECOGNITION; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; HL-60 CELLS; HLA-A1 ANTIGEN; HLA-A2 ANTIGEN; HUMANS; K562 CELLS; LEUKEMIA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0033843385     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00053-9     Document Type: Article

References (49)

1. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner D., Storb E. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. New Engl. J. Med. 300:1979;1068.
2. Brenner M.K., Heslop H.E. Immunotherapy of leukemia. Leukemia. 6(suppl 1):1992;76.
3. Barrett J., Malkovska V. The graft-versus-leukemia effect. Curr. Opin. Oncol. 8:1996;89.
4. Foa R., Fierro M.T., Tosti S., Meloni G., Gavosto F., Mandelli F. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk. Lymph. 1:1990;113.
5. Maraninchi D., Blaise D., Viens P. et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 78:1991;2182.
6. Benyunes M.C., Higuchi C., York A., Lindgren C., Thompson J.A., Buckner C.D., Fefer A. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transpl. 16:1995;283.
7. Blaise D., Olive D., Michalet M., Marit G., Leblond V., Maraninchi D. Impairement of leukemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet. 345, 8958:1995;1144-1146.
8. Kolb H.J., Scgattenberg A., Goldman J.M. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 86:1995;2041.
9. Mackinnon S., Papadopoulos E.B., Carabasi M.H. et al. Adoptive immunotherapy evaluating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia response from graft-versus-host disease. Blood. 86:1995;1261.
10. Hercend T., Takvorian T., Nowill A. et al. Characterization of natural killer cells with antileukemic activity after allogeneic bone marrow transplantation. Blood. 67:1986;722.
11. Apperley J.F., Jones L., Hale G., Goldman J.M. Bone marrow transplantation for patients with chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of graft versus host disease but may increase the risk of leukemia relapse. Bone Marrow Transpl. 1:1988;53.
12. Lotzova E., Savary C.A., Herbeman R.B. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J. Immunol. 138:1987;2718.
13. Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizogushi H. Cytotoxicity of interleukin-2 activated lymphocytes for leukemic and lymphoma cells. Blood. 68:1986;938.
14. Bensussan A., Lagabrielle J., Degos L. TCR γδ bearing lymphocyte clones with lymphokine-activated killer against autologous leukemic cells. Blood. 73:1989;2077.
15. Sosman J.A., Oettel K.R., Smith S.D., Hank J.A., Fisch P., Sondel P.M. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood. 75:1990;2005.
16. van der Harst D., Goulmy E., Falkenburg J.H.F., Kooy-Winkelaar Y.M.C., Luxenburg-Heijs S.A.P., Goselink H.M., Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemia cells by cytotoxic T-cell clones. Blood. 83:1995;1060.
17. Faber LM, van der Hoever, Goulmy E, Hooftman-den Otter AL, Luxenburg-Heijs SAP, Willemze R, Falkenburg JHF. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic lymphocytes. J Clin Invest 1995;96:877.
18. Wang W., Meadowa L.M., Den Hann J.M.M. et al. Human H-Y: a male-specific histocompatibility antigen dervied from the SMCY protein. Science. 269:1995;1588.
19. Den Haan J.M.M., Sherman N.E., Blokland Y. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 279:1998;1054.
20. Boon T. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:1996;725.
21. Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P.P., Pelicci P., Parmiani G. Human cd4+ lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML-RARa present in acute promyelocytic cells. Blood. 81:1993;1369.
22. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A., Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85:1995;2680.
23. Ten Bosch G.J.A., Toornvielt A.C., Friede T., Melief C.J.M., Leeksma O.C. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia. 9:1995;1344.
24. Yotdna P., Garcia F., Peuchmaur M. et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102:1998;455.
25. Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., Tadokoro K., Juji T. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myelogenous leukemia. Blood. 91:1998;977.
26. Noto T., Takahashi Y., Makiguchi Y., Hayashi Y., Hinoda Y., Imai K. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int. Immunol. 9:1997;791.
27. Sing A.P., Ambinder R.F., Hong D.J., Jensen M., Batten W., Petersdorff E., Greenberg P.D. Isolation of Epstein-Barr virus specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy for EBV+ Hodgkin's disease. Blood. 89:1997;1978.
28. van den Bruggen P., Traversari C., Chomez P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643.
29. Brasseur F., Marchand M., Vanwuck R., Herin M., Lethé B., Chomez P., Boon T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int. J. Cancer. 52:1992;839.
30. de Plaen E., Arden K., Traversari C. et al. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics. 40:1994;360.
31. Traversari C., van den Bruggen P., Luerscher I.F. et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by CTL directed against tumor antigen MZ2-E tumors. J. Exp. Med. 176:1992;1453.
32. van den Bruggen P., Bastin J., Gajewski T. et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:1994;3038.
33. Chambost H, Brasseur F, de Plaen E, Stoppa Am, Baume D, Mannoni P, Boon T, Maraninchi D, Olive D. A tumour-associated antigen expression in human haematological malignancies. Br J Haematol 1993;84:524.
34. Schichijo S., Tsunosue R., Masuoka K., Natori H., Tamai M., Miyajima J., Sagawa K., Itoh K. Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunol. Immunother. 41:1995;95.
35. van Baren N., Brasseur F., Godelaine D. et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 94:1999;1156.
36. Chambost H, van Baren N, Brasseur F, Godelaine D, Theate I, Spagnoli GC, Xerri L, Plumas J, Michel G, Coulie PG, Olive D. Expression of gene MAGE4-A4 in Reed Sternberg cells. Blood 2000;95(11):(in press).
37. Traversari C., van den Bruggen P., van den Eynde B. et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics. 35:1992;145.
38. Salter R.D., Howell D.N., Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphocyte. Immunogenetics. 21:1985;235.
39. Gaugler B., van den Eynde B., van den Bruggen P. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:1994;921.
40. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203.
41. Boon T., van Snick J., van Pel A., Uyttenhove C., Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152:1980;1184.
42. Marchand M., van Baren N., Weynants P. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA A1. Int. J. Cancer. 80:1999;219.
43. Valmori D., Gileadi U., Servis C. et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:1999;895.
44. Restifo NP, Marincola FM, Kawakami Y, Taubenberger Y, Tannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. JNCI:1996; 88:100.
45. Dermine S., Mavroudis D., Jiang Y.Z., Hensel N., Molldrem J., Barrett A.J. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transpl. 19:1996;989.
46. Lethe B., van der Bruggen P., Brasseur F., Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 7(Suppl 2):1997;S83-S88.
47. De Smet C., de Backer O., Faraoni I., Lurquin C., Brasseur F., Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. PNAS. 93:1996;7149.
48. Schichijo S., Yamada A., Sagawa K., Iwamoto M., Sakata M., Nagai K., Itoh K. Induction of MAGE genes in lymphoid cells by demethylating agent 5-aza-2′-deoxycytidine. Jpn. J. Cancer Res. 87:1996;751.
49. Delain M., Tiberghien P., Racadot E. et al. Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia. 8:1994;642.